The Russian drugmaker Axelpharm will continue sales of its drug axitinib, which is used in kidney cancer therapy and is a generic of version of US pharma giant Pfizer’s (NYSE: PFE) Inlyta, reports The ...

Precision medicine has advanced significantly over the past decade, driven by breakthroughs in chemical, hardware, software, and especially cloud computing technologies. However, the next big ...

Abalone Bio, an antibody company measuring large-scale activity data to drive AI-powered discovery of active therapeutics, ...

Sales of antidepressants in Russia during the period of January-February 2025 amounted to 2.8 billion roubles ($30 million) ...

The Roche subsidiary Genentech has presented five-year SUNFISH data on Evrysdi (risdiplam) in the final readout of this ...

AstraZeneca (LSE: AZN) today revealed it has entered into a definitive agreement to acquire EsoBiotec, a Belgium-based ...

Anglo-Swedish pharma major AstraZeneca and Korean biotech Alteogen have entered into an exclusive license agreement for ...

Switzerland-headquartered iOnctura today announced the appointments of Elizabeth Holt as chief business officer (CBO) and Dr ...

California-based Latigo Biotherapeutics, a biotech developing non-opioid pain treatments, has closed $150 million in a Series B financing.

Hours after the swearing-in of the Secretary of Health and Human Services, Robert F Kennedy Jr (RFK), President Donald Trump issued an executive order establishing the Make America Healthy Again ...

High-level results from the CALYPSO Phase III trial showed that eneboparatide (AZP-3601), an investigational parathyroid hormone (PTH) receptor 1 agonist, met its primary endpoint with statistical ...

The European Commission (EC) has granted approval to Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric ...